Entera Bio (NASDAQ:ENTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Entera Bio (NASDAQ:ENTX) announced its earnings results on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05), FiscalAI reports.

Entera Bio Stock Up 5.0%

ENTX traded up $0.15 during trading on Friday, reaching $3.14. 117,978 shares of the company’s stock were exchanged, compared to its average volume of 598,459. Entera Bio has a fifty-two week low of $0.91 and a fifty-two week high of $4.20. The business has a 50 day moving average price of $2.88 and a 200 day moving average price of $1.95. The company has a market capitalization of $546.11 million, a P/E ratio of -8.97 and a beta of 1.48.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Lifesci Capital assumed coverage on shares of Entera Bio in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price for the company. Leerink Partners began coverage on shares of Entera Bio in a research report on Friday, September 18th. They issued an “outperform” rating and a $9.00 price target on the stock. Wall Street Zen lowered shares of Entera Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday. Guggenheim assumed coverage on shares of Entera Bio in a report on Thursday, September 24th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, UBS Group set a $9.00 price objective on shares of Entera Bio in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.60.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.